NFKB1 and systemic lupus erythematosus: For example, artemisinin and its derivatives inhibit NF-κB by silencing these upstream pathways and/or directly binding to NF-κB, which alleviates the severity of systemic lupus erythematosus (SLE), autoimmune encephalitis (AE), dermatitis, IBD, autoimmune hepatitis, and autoimmune thyroiditis [139].